Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOOL-pneumo study of infant pneumococcal vaccine switch and RSV monoclonal antibody impact
NL-OMON61451Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of pneumococcal conjugate vaccine and nirsevimab in pneumococcal disease, respiratory syncytial virus disease (RSV) and Respiratory viral illness (3 cohorts), sponsored by University Medical Center Utrecht. Primary endpoints: Association between PCV10 versus PCV15 period and serotype-specific pneumococcal carriage and density, Association of pneumococcal carriage with number of viral infections and 4 more. Started Oct 2026; status: recruiting.
02
Drugs
pneumococcal conjugate vaccinenirsevimab
03
Conditions
pneumococcal diseaserespiratory syncytial virus disease (RSV)Respiratory viral illness
Beyond the preview
Go deeper on NL-OMON61451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61451.